FI113241B - Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi - Google Patents

Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi Download PDF

Info

Publication number
FI113241B
FI113241B FI960750A FI960750A FI113241B FI 113241 B FI113241 B FI 113241B FI 960750 A FI960750 A FI 960750A FI 960750 A FI960750 A FI 960750A FI 113241 B FI113241 B FI 113241B
Authority
FI
Finland
Prior art keywords
ngf
formulation
growth factor
formulations
nerve growth
Prior art date
Application number
FI960750A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI960750A (fi
FI960750A0 (fi
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI960750A0 publication Critical patent/FI960750A0/fi
Publication of FI960750A publication Critical patent/FI960750A/fi
Application granted granted Critical
Publication of FI113241B publication Critical patent/FI113241B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI960750A 1993-08-20 1996-02-19 Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi FI113241B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10979893 1993-08-20
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor
US9409245 1994-08-16

Publications (3)

Publication Number Publication Date
FI960750A0 FI960750A0 (fi) 1996-02-19
FI960750A FI960750A (fi) 1996-02-20
FI113241B true FI113241B (fi) 2004-03-31

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960750A FI113241B (fi) 1993-08-20 1996-02-19 Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi

Country Status (32)

Country Link
US (2) US6277828B1 (ru)
EP (1) EP0721343B1 (ru)
JP (2) JP4592830B2 (ru)
KR (1) KR100341193B1 (ru)
CN (1) CN1163265C (ru)
AT (1) ATE226085T1 (ru)
AU (1) AU677699B2 (ru)
BG (1) BG62951B1 (ru)
BR (1) BR9407278A (ru)
CA (1) CA2169834C (ru)
CZ (1) CZ292422B6 (ru)
DE (1) DE69431562T2 (ru)
DK (1) DK0721343T3 (ru)
ES (1) ES2181723T3 (ru)
FI (1) FI113241B (ru)
HK (1) HK1012990A1 (ru)
HU (1) HU228152B1 (ru)
IL (3) IL110725A (ru)
LT (1) LT4051B (ru)
LV (1) LV11279B (ru)
NO (1) NO317627B1 (ru)
NZ (1) NZ271873A (ru)
PL (1) PL176387B1 (ru)
PT (1) PT721343E (ru)
RO (1) RO114742B1 (ru)
RU (1) RU2126265C1 (ru)
SI (1) SI9420048B (ru)
SK (1) SK284064B6 (ru)
TW (1) TW427905B (ru)
UA (1) UA43348C2 (ru)
WO (1) WO1995005845A1 (ru)
ZA (1) ZA946333B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
AU721869B2 (en) * 1995-05-12 2000-07-13 Brigham And Women's Hospital Treatment of alzheimer disease by modulation of synapsins
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
CA2234231C (en) * 1995-11-07 2009-04-14 Genentech, Inc. Stabilizing formulation for ngf
CA2256333A1 (en) * 1996-05-29 1997-12-04 Victor Bronshtein Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
DK0994721T3 (da) * 1997-05-01 2007-04-02 Protechtion Unltd Inc Nervevækstfaktor som vaccineadjuvans
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
EP1019081A2 (en) * 1997-09-30 2000-07-19 Duke University Apolipoprotein e/growth factor complexes and methods of use
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
JP4648002B2 (ja) 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
RU2005132164A (ru) * 2003-03-18 2006-06-10 Ново Нордиск Хелт Кэр Аг (Ch) Жидкие, водные фармацевтические композиции полипептидов фактора vii
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1628677B1 (en) * 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
AU2004264282B2 (en) * 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
PT2298287T (pt) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Composições estabilizadas de polipéptidos de fator vii
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2008020584A1 (fr) * 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Préparation lyophilisée stable
ES2549790T3 (es) * 2006-11-08 2015-11-02 P Mind Co., Ltd Aparato para acelerar la producción de factor neurotrófico
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2738274A1 (fr) * 2008-09-26 2010-04-01 Adocia Complexe constitue d'un polysaccharide et d'une hpb
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
DK2694094T3 (da) 2011-04-07 2017-11-13 Neovacs FREMGANGSMÅDE TIL BEHANDLING AF IFN-alpha-RELATEREDE TILSTANDE
US20150005236A1 (en) * 2012-02-08 2015-01-01 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
DK3287139T3 (da) * 2015-04-21 2021-09-13 Beijing Staidson Medical Tech Co Ltd Nervevækstfaktorsammensætning og injektionspulver
CN107660149B (zh) * 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物及注射粉剂
WO2016169455A1 (zh) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物和注射粉剂
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
CA3018473A1 (en) 2016-03-25 2017-09-28 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
EP4019007A1 (en) * 2016-06-01 2022-06-29 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
CZ292422B6 (cs) 2003-09-17
LT4051B (en) 1996-10-25
CN1163265C (zh) 2004-08-25
PT721343E (pt) 2003-01-31
AU7566894A (en) 1995-03-21
NO960651D0 (no) 1996-02-19
EP0721343B1 (en) 2002-10-16
LV11279A (lv) 1996-06-20
JP4592830B2 (ja) 2010-12-08
IL110725A0 (en) 1994-11-11
DK0721343T3 (da) 2003-02-17
IL124941A0 (en) 1999-01-26
PL313084A1 (en) 1996-05-27
LV11279B (en) 1996-10-20
ATE226085T1 (de) 2002-11-15
US7074763B2 (en) 2006-07-11
PL176387B1 (pl) 1999-05-31
KR100341193B1 (ko) 2002-06-21
SI9420048B (sl) 2003-12-31
HUT74728A (en) 1997-02-28
US6277828B1 (en) 2001-08-21
JP2007314572A (ja) 2007-12-06
ES2181723T3 (es) 2003-03-01
IL124941A (en) 2006-12-10
US20010007662A1 (en) 2001-07-12
RO114742B1 (ro) 1999-07-30
BG100371A (bg) 1996-12-31
BG62951B1 (bg) 2000-12-29
EP0721343A1 (en) 1996-07-17
HU228152B1 (en) 2012-12-28
CN1133012A (zh) 1996-10-09
CA2169834C (en) 2008-11-04
BR9407278A (pt) 1996-10-01
CA2169834A1 (en) 1995-03-02
NZ271873A (en) 1996-10-28
SK284064B6 (sk) 2004-09-08
CZ42496A3 (en) 1996-05-15
UA43348C2 (ru) 2001-12-17
FI960750A (fi) 1996-02-20
NO317627B1 (no) 2004-11-29
LT96011A (en) 1996-07-25
DE69431562T2 (de) 2003-06-18
WO1995005845A1 (en) 1995-03-02
HK1012990A1 (en) 1999-08-13
NO960651L (no) 1996-02-19
RU2126265C1 (ru) 1999-02-20
TW427905B (en) 2001-04-01
ZA946333B (en) 1996-02-19
DE69431562D1 (de) 2002-11-21
SI9420048A (en) 1996-10-31
SK18396A3 (en) 1996-10-02
HU9600371D0 (en) 1996-04-29
JPH10508000A (ja) 1998-08-04
IL110725A (en) 2004-09-27
AU677699B2 (en) 1997-05-01
FI960750A0 (fi) 1996-02-19

Similar Documents

Publication Publication Date Title
FI113241B (fi) Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi
US5981485A (en) Human growth hormone aqueous formulation
CA2139358C (en) Human growth hormone aqueous formulation
US5763394A (en) Human growth hormone aqueous formulation
KR100310796B1 (ko) 신경생육인자약학배합물

Legal Events

Date Code Title Description
MA Patent expired